Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 25, 2021 07:30 ET | Source: Abeona Therapeutics Inc.

Abeona Therapeutics Announces Successful Type B Meeting with FDA for Pivotal Phase 3 VIITAL™ Study of EB-101 in Recessive Dystrophic Epidermolysis Bullosa (RDEB)

NEW YORK and CLEVELAND, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the company held a...
December 21, 2020 12:20 ET | Source: Abeona Therapeutics Inc.

Abeona Therapeutics Announces Acceptance of Late-Breaker Abstracts Highlighting New Clinical Data for Novel AAV-based Gene Therapies in MPS IIIA and MPS IIIB at WORLDSymposium™

NEW YORK and CLEVELAND, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that abstracts detailing new...
November 09, 2020 16:05 ET | Source: Abeona Therapeutics Inc.

Abeona Therapeutics Reports Third Quarter Financial Results

NEW YORK and CLEVELAND, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced financial results for the third...
October 27, 2020 06:30 ET | Source: Abeona Therapeutics Inc.

Abeona Therapeutics Announces the Appointment of Michael Amoroso as Chief Operating Officer

NEW YORK and CLEVELAND, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Michael Amoroso, Senior...
October 06, 2020 16:01 ET | Source: Abeona Therapeutics Inc.

Abeona Therapeutics’ Board of Directors Forms Special Committee to Oversee Operations, Develop Strategic Direction and Leadership Plan

Steven H. Rouhandeh Appointed as Chairman of the Board of Directors Jefferies LLC Retained as Financial Advisor to Assist with the Review of Strategic Options NEW YORK and CLEVELAND, Oct. 06,...
September 28, 2020 09:27 ET | Source: Abeona Therapeutics Inc.

Abeona Therapeutics Announces Leadership and Board Transitions

NEW YORK and CLEVELAND, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced changes in its executive...
September 08, 2020 16:05 ET | Source: Abeona Therapeutics Inc.

Abeona Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK and CLEVELAND, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the Company will...
August 17, 2020 07:00 ET | Source: Abeona Therapeutics Inc.; Taysha Gene Therapies

Abeona Therapeutics and Taysha Gene Therapies Enter into Licensing and Inventory Purchase Agreements for ABO-202, a Clinical Stage, Novel, One-time Gene Therapy for CLN1 Disease

NEW YORK and CLEVELAND and DALLAS, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, and Taysha Gene Therapies, a...
August 11, 2020 16:46 ET | Source: Abeona Therapeutics Inc.

Abeona Therapeutics annonce ses résultats financiers et mises à jour du deuxième trimestre

Des patients supplémentaires ont reçu des doses dans le cadre des programmes cliniques sur l'EBDR, le MPS IIIA et le MPS IIIB Alignement général par rapport aux plans d'enregistrement dans l'UE de...
August 11, 2020 16:46 ET | Source: Abeona Therapeutics Inc.

Abeona Therapeutics gibt Geschäftsergebnisse für das zweite Quartal und Unternehmensneuigkeiten bekannt

Weitere Patienten in den klinischen Programmen zu RDEB, MPS IIIA und MPS IIIB behandelt Allgemeine Abstimmung mit dem CHMP über Pläne zur EU-Registrierung von ABO-102 für MPS IIIA Daten aus RDEB-...